Wallin MT, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029–40.

Article  PubMed  PubMed Central  Google Scholar 

Baird JF, Sandroff BM, Motl RW. Therapies for mobility disability in persons with multiple sclerosis. Expert Rev Neurother. 2018;18(6):493–502.

Article  CAS  PubMed  PubMed Central  Google Scholar 

LaRocca NG. Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient. 2011;4:189–201.

Article  PubMed  Google Scholar 

Motl RW, McAuley E. Symptom cluster and quality of life: preliminary evidence in multiple sclerosis. J Neurosci Nurs. 2010;42(4):212–6.

Article  PubMed  PubMed Central  Google Scholar 

Sandroff BM, Sosnoff JJ, Motl RW. Physical fitness, walking performance, and gait in multiple sclerosis. J Neurol Sci. 2013;328(1–2):70–6.

Article  PubMed  Google Scholar 

Rae-Grant A, et al. Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):789–800.

Article  PubMed  Google Scholar 

Hemmett L, et al. What drives quality of life in multiple sclerosis? QJM. 2004;97(10):671–6.

Article  CAS  PubMed  Google Scholar 

Vargas DL, Tyor WR. Update on disease-modifying therapies for multiple sclerosis. J Investig Med. 2017;65(5):883–91.

Article  PubMed  Google Scholar 

Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. In: Mayo Clinic Proceedings. Elsevier; 2014.

Chan A, Heck C. Mobility in multiple sclerosis: more than just a physical problem. Int J MS Care. 2000;2(1):51–61.

Article  Google Scholar 

Giovannoni G, et al. Smouldering multiple sclerosis: the ‘real MS.’ Ther Adv Neurol Diso. 2022;15:17562864211066752.

Article  Google Scholar 

Marrie RA. Comorbidity in multiple sclerosis: implications for patient care. Nat Rev Neurol. 2017;13(6):375–82.

Article  PubMed  Google Scholar 

Motl RW. Ambulation and multiple sclerosis. Phys Med Rehabil Clin. 2013;24(2):325–36.

Article  Google Scholar 

Klaren RE, et al. Objectively quantified physical activity in persons with multiple sclerosis. Arch Phys Med Rehabil. 2013;94(12):2342–8.

Article  PubMed  Google Scholar 

Motl RW. Physical activity and irreversible disability in multiple sclerosis. Exerc Sport Sci Rev. 2010;38(4):186–91.

Article  PubMed  Google Scholar 

Abou L, et al. A nationwide update on prevalence of falls, injurious falls, concerns about falling, and fall prevention in persons with multiple sclerosis. Am J Phys Med Rehabil. 2024;103(9):811–918.

Sosnoff JJ, et al. Mobility, balance and falls in persons with multiple sclerosis. PLoS ONE. 2011;6(11): e28021.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sosnoff JJ, Sung J. Reducing falls and improving mobility in multiple sclerosis. Expert Rev Neurother. 2015;15(6):655–66.

Article  CAS  PubMed  Google Scholar 

Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol. 2005;4(10):643–52.

Article  PubMed  Google Scholar 

Toosy A, Ciccarelli O, Thompson A. Symptomatic treatment and management of multiple sclerosis. Handb Clin Neurol. 2014;122:513–62.

Article  PubMed  Google Scholar 

Ghorbanpour S, et al. Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis. Neurol Sci. 2023;44(9):3059–69.

Article  PubMed  Google Scholar 

Berger JR. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies. Am J Manag Care. 2011;17(5):S146.

PubMed  Google Scholar 

Dalgas U, Stenager E. Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis? Ther Adv Neurol Diso. 2012;5(2):81–95.

Article  Google Scholar 

Feinstein A, Freeman J, Lo AC. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol. 2015;14(2):194–207.

Article  PubMed  Google Scholar 

Newsome SD, et al. A framework of care in multiple sclerosis, part 2: symptomatic care and beyond. Int J MS Care. 2017;19(1):42–56.

Article  PubMed  PubMed Central  Google Scholar 

Charron S, McKay KA, Tremlett H. Physical activity and disability outcomes in multiple sclerosis: a systematic review (2011–2016). Mult Scler Relat Diso. 2018;20:169–77.

Article  Google Scholar 

Edwards T, Pilutti LA. The effect of exercise training in adults with multiple sclerosis with severe mobility disability: a systematic review and future research directions. Mult Scler Relat Diso. 2017;16:31–9.

Article  Google Scholar 

Dalgas U. Rehabilitation and multiple sclerosis: hot topics in the preservation of physical functioning. J Neurol Sci. 2011;311:S43–7.

Article  PubMed  Google Scholar 

Plummer P, Markovic-Plese S, Giesser B. Dalfampridine for mobility limitations in people with multiple sclerosis may be augmented by physical therapy: a non-randomized two-group proof-of-concept pilot study. Front Rehabil Sci. 2022;2: 795306.

Article  PubMed  PubMed Central  Google Scholar 

Munn Z, et al. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18:1–7.

Article  Google Scholar 

Murray TJ. Multiple sclerosis: the history of a disease. New York: Demos Medical Publishing; 2004.

Google Scholar 

Orrell RW. Multiple sclerosis: the history of a disease. J R Soc Med. 2005;98(6):289.

Article  PubMed Central  Google Scholar 

Stüve O, et al. Approved and future pharmacotherapy for multiple sclerosis. Neurologist. 2002;8(5):290–301.

Article  PubMed  Google Scholar 

Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):65–94.

Article  Google Scholar 

Cashin AG, McAuley JH. Clinimetrics: physiotherapy evidence database (PEDro) scale. J Physiother. 2020;66(1):59.

Article  PubMed  Google Scholar 

Shi J, Wu X, Chen Y. Study on dalfampridine in the treatment of multiple sclerosis mobility disability: a meta-analysis. PLoS ONE. 2019;14(9): e0222288.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang E, et al. Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials. Orphanet J Rare Dis. 2021;16:1–12.

Article  Google Scholar 

Valet M, et al. Effects of fampridine in people with multiple sclerosis: a systematic review and meta-analysis. CNS Drugs. 2019;33:1087–99.

Article  CAS  PubMed  Google Scholar 

Goodman A, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 2008;71(15):1134–41.

Article  CAS  PubMed  Google Scholar 

Goodman AD, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010;68(4):494–502